Title: Freeze-drying protocol for liposomes co-encapsulating fisetin and cisplatin

Morgane RENAULT-MAHIEUX[1,2], Muriel PAUL[1], Karine ANDRIEUX [2],

[1]AP-HP, Henri Mondor Hospital Group, Pharmacy Department, 51 avenue du Maréchal de Lattre de Tassigny, 94010 Créteil, France
[2]Paris Descartes University, UTCBS, INSERM U1022 UMR CNRS 8258, 4 avenue de l'observatoire, 75006 Paris, France, karine.andrieux@parisdescartes.fr

Keywords: liposomes, freeze-drying, fisetin, cisplatin, glioblastoma

I. Abstract Body (up to 250 words):

In order to fight against glioblastoma, the antiangiogenic fisetin and the anticarcinogenic cisplatin were co-encapsulated in liposomes (75.3%mol of DOPC, 20.8%mol of cholesterol and 3.9%mol of DODA-Gly-PEG ; 8.5 mg of cisplatin/g of lipids and 15.5 mg of fistein/g of lipids). However, its stability needed to be improved. Indeed, 74.4 ± 0.7% of the fisetin and 35.2 ± 3.1% of cisplatin were released after 10 days. TEM highlighted a disruption of the liposomal bilayers (figure 1) explaining that the liposomal suspension was not stable, and that the release of the two drugs was higher when co-encapsulated than when alone in the liposomes.

Freeze-drying is a process used to ensure the long-term stability of liposomes. The present study investigated the protective capacity of two lyoprotectants, sucrose and trehalose, at 3 concentrations, 5, 10 and 20%, during the freeze-drying of empty liposomes (75.3%mol of DOPC, 20.8%mol of cholesterol and 3.9%mol of DODA-Gly-PEG). Among these, only a 20% concentration of lyoprotectant could prevent the macroscopically aggregation of liposomes. Trehalose 20% could not prevent some aggregation and an increase in size and PDI. Sucrose 20% had the best protective effect concerning size (154.7 ± 1.3nm before freeze-drying and 155.5 ± 2.2nm after rehydration, NS) and PDI (0.094 ± 0.023 before freeze-drying and 0.121 ± 0.019 after rehydration, $p < 0.05$) of empty liposomes (figure 2). Sucrose 20% was chosen for further investigation: water content, freezing protocol and encapsulation of cisplatin and fisetin after freeze-drying and rehydration.

II. Image:




Figure 1 – Transmission electron microscopy photographs of fisetin and cisplatin-loaded liposomes at day 3




Figure 2 – Effect of sucrose 20% and trehalose 20% as lyoprotectants during freeze-drying of empty liposomes

III. Reference:

1. Bhat, T. A., *et al*., Fisetin inhibits various attributes of angiogenesis in vitro and in vivo--implications for angioprevention. *Carcinogenesis* 33, 385–393 (2012)
2. Sheleg, S. V. *et al.* Local chemotherapy with cisplatin-depot for glioblastoma multiforme. *J. Neurooncol.* **60,** 53–59 (2002)
3. Chen, C., *et al*. An overview of liposome lyophilization and its future potential. *J. Controlled Release* 142, 299–311 (2010)

IV. Biography:

Morgane Renault-Mahieux is a 26 years old PhD Scholar in pharmaceutical technologies at the Paris Descartes University, France.

V. Presenting author details:

Full Name: Morgane Renault-Mahieux
Contact number: +33 6 85 61 29 73
Twitter account: @rm_morgane
Linked In account: linkedin.com/in/morgane-renault-mahieux-8a476892
Session name/ number: 11
Category: Oral presentation
Passport Number: 09PE63662